Paolo Ghia, MD

Paolo Ghia, MD, PhD, discusses the takeaways from the final analysis of the phase 2 CAPTIVATE study in CLL.

Paolo Ghia, MD, PhD, discusses results from the final analysis of the CAPTIVATE study in CLL/SLL.

Paolo Ghia, MD, PhD, discusses the final analysis of the CAPTIVATE study.

Paolo Ghia, MD, discusses the implications of the long-term follow-up of the CAPTIVATE trial investigating ibrutinib and venetoclax in CLL.

Paolo Ghia, MD, PhD, discusses the CAPTIVATE trial in chronic lymphocytic leukemia/small lymphocytic lymphoma, and what findings from the trial have been particularly noteworthy.

Paolo Ghia, MD, PhD, provides an overview of the CAPTIVATE trial, uncovering what investigators sought to evaluate.

Paolo Ghia, MD, PhD, discusses the key takeaways from 5-year data follow-up data from the phase 2 CAPTIVATE trial of ibrutinib plus venetoclax for the treatment of patients with chronic lymphocytic leukemia and/or small lymphocytic lymphoma.

Paolo Ghia, MD, PhD, discusses safety and efficacy findings from a 5-year update of the phase 2 CAPTIVATE trial for chronic lymphocytic leukemia and/or small lymphocytic lymphoma treatment.

Paolo Ghia, MD, PhD, discusses background of the phase 2 CAPTIVATE trial.

Addressing the need for treatments that are more effective and less toxic for patients with relapsed or refractory chronic lymphocytic leukemia, Paolo Ghia, MD, of the Universita Vita-Salute San Raffaele, and other researchers conducted a phase III randomized, multicentric ASCEND study, testing acalabrutinib monotherapy in comparison with physician’s choice of standard regimens in patients R/R CLL.